Tradipitant Cuts GLP-1 Vomiting in Phase 3 Trial

Vanda Pharmaceuticals reports positive topline results from Study 3601 testing tradipitant for vomiting linked to GLP-1 drugs.

Updated on Nov. 4, 2026 in Diabetes

Clear glass beakers and a vial rack on a pale laboratory bench under soft window daylight. — Vanda Pharmaceuticals said its phase 3 Study 3601 found tradipitant reduced vomiting induced by GLP-1 drugs, and it plans to seek an expanded indication. AI Illustration. Upload story photo >

Live Poll

Would you trust a new medication to ease nausea from weight-loss drugs?

Vanda Pharmaceuticals announced positive topline results from phase 3 Study 3601, which tested tradipitant for preventing vomiting induced by GLP-1 medications. The company plans to submit a supplemental New Drug Application seeking an expanded indication.

Why it matters

Nausea and vomiting are common side effects of GLP-1 drugs used for weight management and diabetes, and the trial results suggest a possible option for managing them. The planned filing would seek to extend tradipitant's use beyond its currently approved indication for motion-induced vomiting.

The phase 3 trial randomized 306 adults with obesity or overweight and at least one weight-related comorbidity, with 142 assigned to tradipitant and 164 to placebo, and overall vomiting fell 27% relative to placebo (43% vs 58.5%). Exploratory analyses showed larger relative reductions in frequent multi-day vomiting (60%) and extreme vomiting (81%), but the source does not indicate whether these endpoints were prespecified for confirmation.

The players

Vanda Pharmaceuticals

Vanda Pharmaceuticals is a U.S. biopharmaceutical company that develops and markets treatments for central nervous system and sleep disorders, and it markets tradipitant under the brand name Nereus.

The details

Participants received a 1mg semaglutide challenge dose before being randomized to take tradipitant or placebo orally twice daily for about two weeks. Vomiting was tracked using the Nausea Vomiting Daily Diary over 24-hour periods, and the company reported no new safety signals.

October 27, 2026: Vanda announces Study 3601 positive results in a news release.
November 4, 2026: Renal and Urology News publishes coverage of the Study 3601 results.

Health Landscape

The trial extends Nereus, already approved for motion-induced vomiting, into the growing category of vomiting caused by GLP-1 weight-loss and diabetes drugs. Its planned supplemental filing would mark a shift from the compound's current approved use toward treating a side effect that has become common as these medications spread.

For people taking GLP-1 medications who struggle with nausea or vomiting, the results point to a potential future treatment option, though tradipitant is not yet approved for this use. Anyone experiencing these side effects should discuss management options with their prescribing clinician in the meantime.

The takeaway

Vomiting linked to GLP-1 drugs is a treatable side effect under investigation, and the trial suggests a targeted option may be possible. Patients experiencing it should keep their care team informed while more data and regulatory review develop.

What happens next

Vanda plans to submit a supplemental New Drug Application seeking an expanded indication for GLP-1-induced vomiting, but no submission date is specified in the source.